Quince Therapeutics, Inc. (QNCX) has a negative trailing P/E of -0.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 8.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -785.22%, forward earnings yield 11.76%. PEG 0.13 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 47/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -57.9 | 0.00 | -34.95 | 0.00 | - |
| 2018 | -56.8 | -32.38 | 9.92 | 0.00 | - |
| 2019 | -28.9 | -0.12 | 9.25 | 0.00 | - |
| 2020 | -10.5 | -0.29 | 4.71 | 0.00 | - |
| 2021 | -4.2 | -0.27 | 3.16 | 0.00 | - |
| 2022 | -0.4 | 0.01 | 0.21 | 0.00 | - |
| 2023 | -1.2 | 0.03 | 0.46 | 0.00 | - |
| 2024 | -1.4 | -0.03 | 2.68 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-0.57 | $0.00 | $-12.24M | - |
| 2018 | $-0.58 | $0.00 | $-12.48M | - |
| 2019 | $-1.93 | $0.00 | $-36.79M | - |
| 2020 | $-2.63 | $0.00 | $-76.85M | - |
| 2021 | $-3.01 | $0.00 | $-89.33M | - |
| 2022 | $-1.54 | $0.00 | $-51.66M | - |
| 2023 | $-0.84 | $0.00 | $-31.39M | - |
| 2024 | $-1.31 | $0.00 | $-56.83M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.68 | $-0.68 – $-0.68 | $0.00 | $0.00 – $0.00 | 2 |
| 2027 | $-0.05 | $-0.05 – $-0.05 | $17.05M | $17.05M – $17.05M | 1 |
| 2028 | $0.14 | $-0.77 – $1.06 | $292.37M | $292.37M – $292.37M | 2 |
| 2029 | $0.28 | $0.28 – $0.28 | $486.33M | $486.33M – $486.33M | 1 |
| 2030 | $0.40 | $0.40 – $0.40 | $705.84M | $705.84M – $705.84M | 1 |
